AZD5863

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Advanced or metastatic solid tumorsEsophageal AdenocarcinomaGastric CancerGastro-esophageal Junction CancerPancreatic Ductal Adenocarcinoma

Phase 1

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

RecruitingNCT06005493

AstraZenecaEsophageal Adenocarcinoma, Gastric Cancer, Gastro-esophageal Junction Cancer +1

Start: 2023-07-11End: 2027-07-16Target: 280Updated: 2026-02-24

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors.

RecruitingCTIS2023-504139-42-00

AstraZeneca ABAdvanced or metastatic solid tumors

Start: 2024-09-06Target: 48Updated: 2025-11-13

Related Papers

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release

Journal for ImmunoTherapy of Cancer2025-08-01